Glial Replacement Therapy Slows Huntington's Disease in Adult Mice

Glial replacement therapy slows Huntington's disease in adult mice

Huntington's disease has long defied attempts to rescue suffering neurons. A new study in Cell Reports shows that transplanting healthy human glial progenitor cells into the brains of adult animal models of the disease not only slowed motor and cognitive decline but also extended lifespan. These findings shift our understanding of Huntington's pathology and open a potential path to cell-based therapies in adults already showing symptoms.

Glial Cell Transplants Slow Huntington’s Symptoms and Extend Life

A new study reveals that transplanting healthy human glial progenitor cells into adult mice with Huntington’s disease can delay motor and cognitive decline and extend lifespan. These support cells restored key neuronal functions, reversed synaptic damage, and reactivated gene expression even after symptoms began.

NUZ-001 Shows Promise in Zebrafish Model of Huntington's Disease

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Highlights: NUZ-001 and its active metabolite NUZ-001 Sulfone demonstrated significant neuroprotective effects in a zebrafish model of Huntington’s disease Treatment prevented hallmark developmental and morphological abnormalities, protected against neuronal cell death, restored delayed hae…

Positive preclinical data supports potential of Neurizon’s NUZ-001 in Huntington’s disease

Neurizon’s NUZ-001 and active metabolite NUZ-001 Sulfone show strong neuroprotective effects in a zebrafish Huntington’s model Results show potential of drug to counteract early neurodegenerative damage caused by disease Neurizon plans to initiate additional validation studies in mammalian models of Huntington’s   Special Report: Clinical-stage biotech Neurizon Therapeutics has reached a milestone in development of its lead drug candidate NUZ-00…